- PharmAust (PAA) appoints Dr Michael Thurn as its newest CEO, effective September 1
- The company reports he has extensive experience in drug discovery, regulation and clinical trials
- Dr Roger Aston will remain as Chair, but transition into a non-executive role
- PharmAust last traded at 7.4 cents
PharmAust (PAA) has appointed Dr Michael Thurn as its newest Chief Executive Officer, starting from September 1.
The company reported that Dr Thurn brings a wealth of expertise in drug discovery, regulation, and clinical trials.
He previously served as Executive Director of Botanix Pharmaceuticals and was also a former team member of the TGA Drug Safety Evaluation Branch. Dr Thurn has overseen the execution of phase one and two clinical trials.
“This is an incredible opportunity to join PharmAust at this significant point in the company’s journey,” Dr Thrun said.
“We have an exciting and maturing animal health and human pipeline, an excellent Board and world-class clinical advisors and collaborators to draw knowledge.
Dr Thurn will receive an annual gross salary of $270,270.
Meanwhile, the company announced that Dr Roger Aston will remain as Chair but transition into a non-executive role.
PharmAust last traded at 7.4 cents.